Vaccitech

Antigen-specific immunotherapy is the clinical focus of Barinthus Biotherapeutics plc (formerly Vaccitech), a clinical-stage biopharmaceutical company dedicated to guiding T cells and antibodies to overcome autoimmunity and inflammatory disease. The company operates at the research and development frontier of immunology and inflammatory (I&I) indications, building on scientific foundations laid by academic institutions of international standing.

Barinthus Bio emerged from the 2021 merger of Vaccitech, Plc, an Oxford University spinout, and Avidea Technologies, Inc., a spinout of the National Institutes of Health (NIH) and Johns Hopkins University. The combination united two complementary immunotherapeutics platforms and created a company with a broader base of T cell-directed therapeutic expertise than either predecessor held independently.

The company's pipeline centres on autoimmunity, with its proprietary SNAP-TI technology supporting the development of tolerance immunotherapies designed to address the underlying drivers of inflammatory disease rather than managing symptoms alone. Barinthus Bio describes its approach as guiding the immune system to cure disease, a distinction it draws between its antigen-specific methodology and broader immunosuppressive strategies common in the I&I space.

Headquartered in the United Kingdom, the company is listed and engages institutional investors through structured governance and regular news and filings activity. Its scientific founders come from leading research institutions, anchoring its discovery capabilities in a heritage of cutting-edge immunological innovation.

Further information is available at vaccitech.co.uk.